PrashantKumar Khirsariya, Ph.D., M.Sc.
Researcher II, Department of Chemistry
Total number of publications: 28
2020
-
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe
Molecular oncology, year: 2020, volume: 14, edition: 10, DOI
2019
-
ATR-CHK1 signaling is active and targetable in quiescent CLL cells
Year: 2019, type: Conference abstract
-
CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes
EMBO reports, year: 2019, volume: 20, edition: 9, DOI
-
Cílená inhibice kasein kinázy 1 v léčbě chronické lymfoidní leukémie.
Year: 2019, type: Conference abstract
-
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
Haematologica, year: 2019, volume: 104, edition: 12, DOI
-
Potenciál inhibice proteinu checkpoint kinase 1 u chronické lymfocytární leukémie s mutacemi v genu TP53.
Year: 2019, type: Conference abstract
2018
-
CDK12 kinase activity controls G1/S progression by regulating optimal transcription of core DNA replication genes
Year: 2018, type: Conference abstract
-
Impact of the access tunnel engineering on catalysis is strictly ligand-specific
the FEBS Journal, year: 2018, volume: 285/2018, edition: 8, DOI
-
Inovativní inhibitor proteinu CHK1 indukuje apoptózu u buněk chronické lymfocytární leukémie s mutacemi v genu TP53
Year: 2018, type: Conference abstract
-
Preparation of 3,4-Substituted-5-Aminopyrazoles and 4 Substituted-2-Aminothiazoles
The Journal of Organic Chemistry, year: 2018, volume: roč. 83, edition: č. 24, DOI